Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Business Insights | The Diabetes Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies

The Diabetes Market Outlook To 2014: Market dynamics, competitive landscape, emerging therapies

The global diabetes market was worth $27.3bn in 2008 and was led by insulin analogs which captured 45.0% of the market followed by glitazones that captured a share of 22.8%. US is the largest diabetes market globally with sales of $12.9b in 2008 and a market share of 47.6%. However the highest growth in sales y-o-y was exhibited by several early emerging economies such as UAE at 59.7%. The diabetes market was led by Novo Nordisk driven primarily by its diverse insulin portfolio. Besides, Novo Nordisk is strengthening its position in the pre-insulin market with its novel insulin analog, Victoza (liraglutide) which recently got an approval in the EU (awaiting US FDA approval). Merck & Co. posted the highest y-o-y growth at 138.6% driven by the sales generated from Januvia, the first-in-class DPP-IV inhibitor. GSK was the only company among the top ten players of the diabetes market to have posted a decline of 40.7%. This decline in the company’s sales has been due to the cardiovascular safety concerns that have mired its leading drug, Avandia’s growth since 2007. The report provides competitive analysis of the leading pharmaceutical companies in the diabetes market, examining their marketed product portfolios and R&D pipelines in order to forecast their future competitive positions.

Published: September 2009 - Global.
Table of Contents
Price: $3,825.00 / €2,556.63

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions